EPO & GSK3beta

 

In 2016, a study I co-authored was ranked amongst the most cited papers in Biological Psychiatry showing that cognitive improvements in EPO-treated patients with mood disorders involves  increased hippocampal volume.

We have now written a Review paper about EPO, cognition, depression and its underlying molecular mechanisms centred around GSK3beta. The manuscript is currently under review with Translational Psychiatry.

 

More information coming soon!